Latest 10-Q quarterly reports

CaliberCos Inc. reported significant operating losses and liquidity concerns in its Q3 2026 10-Q filing, raising substantial doubt about its ability to continue as a going concern, despite ongoing strategic efforts.

Cumberland Pharmaceuticals Inc. reported a substantial net income driven by the sale of its commercial brands to Apotex, while continuing to invest in its innovative drug development pipeline.

Research Alliance Corporation IV, a blank check company, filed its Q3 2026 10-Q, detailing its formation activities, IPO proceeds, and trust account status as it seeks a business combination.

DataMeds AI reported a net income for the quarter driven by debt extinguishment, but faces substantial doubt about its ability to continue as a going concern due to significant working capital deficit and upcoming debt maturities.

GRI Bio, Inc. (GRI) filed its Form 10-Q for the quarter ended September 30, 2026, detailing continued operating losses and significant accumulated deficit, while also reporting positive topline data from its Phase 2a clinical trial for GRI-0621.

Paloma Acquisition Corp I reports net income driven by interest income on trust account assets, with ongoing efforts to identify a suitable business combination target.

Processa Pharmaceuticals reported a substantial net loss for the nine months ended September 30, 2026, but secured $200 million in gross proceeds from a private placement to fund operations and clinical milestones for its lead asset, VT-7208.

Valor Energy Inc. (VAI) filed its Q2 2026 Form 10-Q, reporting a substantial net loss and continued challenges in meeting Nasdaq's minimum stockholder equity requirements, though recent financing and an acquisition target offer potential future upside.

Astrotech Corporation reported a decrease in revenue and a significant drop in gross margin for the third quarter of 2026, while operating expenses were managed down.

Kairos Pharma, Ltd. filed its Q3 2026 10-Q, detailing continued operating losses and substantial doubt regarding its ability to continue as a going concern, while advancing its oncology therapeutics.

Cerenome, Inc. (CNSY) filed its Q3 2026 Form 10-Q, detailing a significant net loss, ongoing liquidity concerns, and potential Nasdaq delisting, while also reporting initial diagnostic revenue and progress in its therapeutic pipeline.

Cheetah Net Supply Chain Service Inc. reported a net loss of $3.1 million for the nine months ended September 30, 2026, driven by operational shifts and acquisition integration, with significant revenue growth from its new international trading segment.

Securitize Corp. announced its Q3 2026 results, showing revenue growth but also significant net losses and increased operating expenses, alongside updates on warrant modifications and business combination accounting.

Vendome Acquisition Corporation I's Q3 2026 filing reveals significant financial challenges and raises substantial doubt about its ability to continue as a going concern, with a mandatory liquidation date approaching.

McKinley Acquisition Corporation's Q3 2026 Form 10-Q details progress on its business combination with Space-Eyes, Inc., alongside continued trust account interest income and operational expenses.

Presidio Property Trust, Inc. reports continued net losses and liquidity challenges in its Q3 2026 filing, despite strategic asset sales.

Healthcare Triangle, Inc. (HCTI) reported a substantial 161% year-over-year revenue increase for Q3 2026, driven by its Customer Engagement Services segment, but also disclosed a widening net loss and ongoing Nasdaq listing concerns.

Fly-E Group's Q2 2026 results show a sharp decline in revenues and widening net losses, exacerbated by ongoing legal challenges and a going concern warning.

Scientific Industries, Inc. filed its Q3 2026 10-Q, revealing a net loss for the nine-month period, though Q3 itself showed a net income, driven by a significant gain from a prior asset disposition.

Positron Corporation reported a net loss of $3.17 million for the nine months ended September 30, 2026, with significant going concern risks despite efforts to secure financing and expand market reach.

Mobiquity Technologies, Inc. filed its Q3 2026 10-Q, detailing a strategic shift towards AI-powered customer acquisition with its GrowthOS and BYOB platforms, alongside a significant net loss.

NMP Acquisition Corp. filed its quarterly report for the period ending September 30, 2026, detailing financial results and significant progress on its business combination with GTS Holdings, LLC.

Stardust Power Inc. reports a significant net loss and faces Nasdaq delisting, raising substantial doubt about its ability to continue as a going concern.

Calidi Biotherapeutics reports significant net losses and accumulated deficit, raising substantial doubt about its ability to continue as a going concern, prompting a 67% workforce reduction.

Twelve Seas Investment Company III reports on its financial condition and operational status for the quarter ending September 30, 2026, highlighting investment income and ongoing efforts to identify a business combination.

Spruce Power Holding Corporation's Q3 2026 10-Q filing reveals substantial doubt about its ability to continue as a going concern due to upcoming debt maturities and negative working capital, despite a return to profitability.

Woodbridge Liquidation Trust reports a slight increase in net assets in liquidation for Q3 2026, but faces ongoing uncertainties from a significant construction defect claim.

Infinite Eagle Acquisition Corp. reports on its financial condition and operational status for the quarter ended September 30, 2026, highlighting its ongoing search for a business combination.

BioScience Health Innovations Inc. reported a net loss of $149,225 for Q3 2026 and a year-to-date loss of $564,885, with revenues declining compared to the prior year, attributed to market adjustments and delayed orders.

Evofem Biosciences' Q3 2026 10-Q filing reveals significant financial distress, with a substantial working capital deficit and an accumulated deficit, raising serious concerns about its ability to continue as a going concern.